Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management

BACKGROUND: Immune checkpoint inhibitors (ICIs) are widely used in cancers with or without other treatments. Immune-related adverse events (irAEs) have been reported as side effects of ICIs and involve various organs. Pneumonitis, which is also called ICI-related interstitial lung disease (ILD), is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seohyun, Lim, Jeong Uk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186237/
https://www.ncbi.nlm.nih.gov/pubmed/35693611
http://dx.doi.org/10.21037/jtd-22-93

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186237/
https://www.ncbi.nlm.nih.gov/pubmed/35693611
http://dx.doi.org/10.21037/jtd-22-93

Ejemplares similares